Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) EPS (Weighted Average and Diluted) (2016 - 2025)

Dexcom (DXCM) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with $0.67 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 76.32% to $0.67 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.09, a 47.18% increase, with the full-year FY2025 number at $2.09, up 47.18% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.67 for Q4 2025 at Dexcom, down from $0.7 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.7 in Q3 2025 to a low of -$1.21 in Q4 2021.
  • A 5-year average of $0.29 and a median of $0.31 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 1110.0% in 2021, then skyrocketed 200.0% in 2024.
  • Dexcom's EPS (Weighted Average and Diluted) stood at -$1.21 in 2021, then soared by 119.01% to $0.23 in 2022, then surged by 165.22% to $0.61 in 2023, then tumbled by 37.7% to $0.38 in 2024, then surged by 76.32% to $0.67 in 2025.
  • Per Business Quant, the three most recent readings for DXCM's EPS (Weighted Average and Diluted) are $0.67 (Q4 2025), $0.7 (Q3 2025), and $0.45 (Q2 2025).